Cantuzumab ravtansine
Based on 1 publication(s) in Google Scholar
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.
For research use only. We do not sell to patients.
- Purity : 98.71%
- CAS No.: 868747-45-9
- Molecular Weight:150000 (average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P99612
Farletuzumab ecteribulinAntibody-Drug Conjugate -
HY-P99829
Cofetuzumab pelidotinPTK7 Inhibitor -
HY-P99547
Trastuzumab duocarmazineHER2-targeted ADC -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-P3371
Ifinatamab deruxtecanDNA Topoisomerase I Inhibitor -
HY-P99681
Labetuzumab govitecanAnti-CEACAM5 ADC
Publications Citing Use of MedChemExpress (MCE) Cantuzumab ravtansine
More
Biological Activity
Description
In Vitro
Cantuzumab ravtansine (huC242-DM4; 5 days) shows cytotoxic effect in CanAg-positive SNU16 gastric cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Cantuzumab ravtansine (huC242-DM4) is also curative in mice bearing human colon tumor xenografts of HT29 and COLO 205 cells, at doses that were non-toxic[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 868747-45-9
-
Appearance Liquid
-
Molecular Weight 150000 (average)
-
Color Colorless to light yellow
-
SMILES
[Cantuzumab ravtansine]
-
Synonyms
IMGN242; huC242-DM4
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
Bottom-Up Protein Analysis Workflow for Simultaneous Characterization of Payloads, Disulfide Bonds, and Free Thiols in Antibody-Drug Conjugates. [Abstract]2025 Dec 30;97(51):28132-28138. PMID: 41400128
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cantuzumab ravtansine Related Classifications
HY-P99493 Related Classifications
Powered by Bioz